CDC updates its child and adolescent and adult immunization schedules every year. These are the main changes in the 2025 schedules, for health care providers.
Child and adolescent schedule
Across the schedule
- Influenza vaccines are now listed in the trivalent formulation rather than quadrivalent, matching the products the FDA approved for the 2024–2025 season; cell culture–based trivalent vaccine (ccIIV3) joins the abbreviations table.
- In Table 1 (by age), the purple legend now includes populations at high risk; in Table 3 (by medical indication), the grey legend now means "no guidance/not applicable".
| Vaccine | What changed |
|---|---|
| COVID-19 | guidance for 2024–2025 vaccines |
| Dengue | recommended only for some children: aged 9–16, living where dengue is endemic, with lab-confirmed past infection |
| DTaP | Td may be used under age 7 when there is a contraindication specific to the pertussis component |
| Hib | Vaxelis or PedvaxHIB preferred for primary doses in American Indian and Alaska Native infants; complement inhibitor use added as a risk factor |
| Hepatitis B | Heplisav-B added to the vaccines that can be given in pregnancy |
| Influenza | optional high-dose (HD-IIV3) or adjuvanted (aIIV3) vaccine for 18-year-old solid organ transplant recipients on immunosuppressants, with no preference over other trivalent vaccines |
| MenB | new Bexsero schedule: for healthy people aged 16–23, 2 doses 6 months apart by shared clinical decision-making, or 3 doses (0, 1–2, 6 months) for faster protection; 3 doses for those 10 and older at increased risk |
| MMR | travel guidance now set out by age and vaccination history |
| Polio | catch-up recommended for persons aged 18 years |
| RSV (nirsevimab) | for infants born October–March, within 1 week of birth, ideally before leaving hospital; for those born April–September, in October–November; also for infants whose mothers were vaccinated in an earlier pregnancy |
| RSV (maternal vaccine) | no extra doses in later pregnancies |
Appendix (contraindications): the statement that Heplisav-B is not recommended in pregnancy, and its registry footnote, were removed; HIV infection of any severity is now a contraindication to MMRV.
Job aids: shared clinical decision-making sheets for HPV vaccination at ages 27–45 and MenB, and catch-up guides for pneumococcal conjugate, Hib (ActHIB, Hiberix, Pentacel, Vaxelis or unknown), Hib (PedvaxHIB), DTaP, IPV, and Tdap for ages 7–9 and 10–18.
Adult schedule
Across the schedule
- Influenza vaccines moved to the trivalent formulation.
- Added to the abbreviations table: adjuvanted, cell culture–based and high-dose trivalent flu vaccines, the newly licensed 21-valent pneumococcal conjugate vaccine (PCV21), and the newly licensed mRNA RSV vaccine.
- In Table 1, the grey legend now means "no guidance/not applicable".
| Vaccine | What changed |
|---|---|
| COVID-19 | guidance for 2024–2025 vaccines |
| Hepatitis B | clearer recommendations for immunocompromised people aged 20 and over; Heplisav-B may be given in pregnancy |
| Influenza | optional HD-IIV3 or aIIV3 for solid organ transplant recipients aged 19–64 on immunosuppressants, with no preference over other trivalent vaccines |
| Polio | inactivated polio vaccine added to Tables 1 and 2 |
| Meningococcal | new Bexsero schedule, as above; 3 doses for adults at increased risk; clarified advice on MenB in pregnancy |
| Mpox | vaccination for occupational risk in health care settings is not routinely recommended for health care personnel |
| Pneumococcal | universal recommendation from age 50; risk-based for ages 19–49; guidance on pregnancy and on what to do when PPSV23 is unavailable |
| RSV | universal from age 75; risk-based for ages 60–74, with the conditions that raise the risk of severe disease |
| Tdap | recommendations set out by previous vaccination history |
Appendix: the Heplisav-B pregnancy statement and footnote were removed, and PCV21 was added to the pneumococcal row.
Sources
- Centers for Disease Control and Prevention, "Schedule Changes & Guidance," immunization schedules for health care providers. https://www.cdc.gov/vaccines/hcp/imz-schedules/changes-guidance.html
Licence: CC0 1.0 (public domain) · Adapted from www.cdc.gov
1
0
0
0
Comments
